Impacts of PEGylation on the gene and oligonucleotide delivery system

Poly(ethylene glycol) (PEG) is the most widely used polymer and also the gold standard in the field of drug delivery. Therapeutic oligonucleotides, for example, are modified with PEG at the terminus to increases nuclease resistance and the circulating half-lives. The surface of nanoparticle such as micelle and liposome has been also modified with PEG. At present, one PEGylated therapeutic oligonucleotide has been approved for the market and several more PEGylated products including oligonucleotide and liposome are being tested in clinical settings. This review summarizes the methods and effects of PEGylation on gene delivery. © 2013 Wiley Periodicals, Inc. J. Appl. Polym. Sci. 2014, 131, 40293.

[1]  Y. Ikada,et al.  Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. , 1994, Journal of pharmaceutical sciences.

[2]  Nobuhiro Nishiyama,et al.  Rational design of smart supramolecular assemblies for gene delivery: chemical challenges in the creation of artificial viruses. , 2012, Chemical Society reviews.

[3]  J. Walder,et al.  Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3' exonuclease in plasma. , 1991, Antisense research and development.

[4]  U. Schubert,et al.  Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. , 2010, Angewandte Chemie.

[5]  Paul Yueh-Jen Hsu,et al.  The effect of poly(D,L-lactide-co-glycolide) microparticles with polyelectrolyte self-assembled multilayer surfaces on the cross-presentation of exogenous antigens. , 2008, Biomaterials.

[6]  Yutaka Ikeda,et al.  Ligand-Targeted Delivery of Therapeutic siRNA , 2006, Pharmaceutical Research.

[7]  High-performance immunolatex possessing a mixed-PEG/antibody coimmobilized surface: highly sensitive ferritin immunodiagnostics. , 2009, Analytical chemistry.

[8]  Y. Nagasaki,et al.  Efficient siRNA delivery based on PEGylated and partially quaternized polyamine nanogels: enhanced gene silencing activity by the cooperative effect of tertiary and quaternary amino groups in the core. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[9]  J. M. Harris,et al.  Effect of pegylation on pharmaceuticals , 2003, Nature Reviews Drug Discovery.

[10]  R. Juliano,et al.  Biological barriers to therapy with antisense and siRNA oligonucleotides. , 2009, Molecular pharmaceutics.

[11]  G. Whitesides,et al.  A Survey of Structure−Property Relationships of Surfaces that Resist the Adsorption of Protein , 2001 .

[12]  Y. Leung,et al.  Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. , 2007, Cancer research.

[13]  D. Wyss,et al.  Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. , 2002, Advanced drug delivery reviews.

[14]  K. Thompson,et al.  Discovery and development of therapeutic aptamers. , 2010, Annual review of pharmacology and toxicology.

[15]  H. Harashima,et al.  A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[16]  D. Guyer,et al.  Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease , 2006, Nature Reviews Drug Discovery.

[17]  Teruhiko Yoshida,et al.  Polyethylenimine-mediated gene transfer into pancreatic tumor dissemination in the murine peritoneal cavity , 2001, Gene Therapy.

[18]  John J. Rossi,et al.  The promises and pitfalls of RNA-interference-based therapeutics , 2009, Nature.

[19]  Jiandu Lei,et al.  Comparison of bioactivities of monopegylated rhG-CSF with branched and linear mPEG , 2007 .

[20]  Studies on the adsorption property and structure of polyamine-ended poly(ethylene glycol) derivatives on a gold surface by surface plasmon resonance and angle-resolved X-ray photoelectron spectroscopy. , 2009, Langmuir : the ACS journal of surfaces and colloids.

[21]  Yukio Nagasaki,et al.  Construction of a densely poly(ethylene glycol)-chain-tethered surface and its performance , 2011 .

[22]  Y. Nagasaki,et al.  PEGylation Technology in Nanomedicine , 2011 .

[23]  F. Davis,et al.  Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. , 1977, The Journal of biological chemistry.

[24]  A. Jungbauer,et al.  Effect of oriented or random PEGylation on bioactivity of a factor VIII inhibitor blocking peptide , 2006, Biotechnology and bioengineering.

[25]  Thomas Tuschl,et al.  Structural basis for 5′-end-specific recognition of guide RNA by the A. fulgidus Piwi protein , 2005, Nature.

[26]  Kazunori Kataoka,et al.  Lactosylated poly(ethylene glycol)-siRNA conjugate through acid-labile beta-thiopropionate linkage to construct pH-sensitive polyion complex micelles achieving enhanced gene silencing in hepatoma cells. , 2005, Journal of the American Chemical Society.

[27]  K. G. Rajeev,et al.  Rational design of cationic lipids for siRNA delivery , 2010, Nature Biotechnology.

[28]  A. Tolcher,et al.  A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Y. Quinn,et al.  New detachable poly(ethylene glycol) conjugates: cysteine-cleavable lipopolymers regenerating natural phospholipid, diacyl phosphatidylethanolamine. , 1999, Bioconjugate chemistry.

[30]  Suntharampillai Thevuthasan,et al.  PEGylated inorganic nanoparticles. , 2011, Angewandte Chemie.

[31]  F. Veronese,et al.  PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity. , 2005, Bioconjugate chemistry.

[32]  O. Eickelberg,et al.  Inflammatory responses to pulmonary application of PEI-based siRNA nanocarriers in mice. , 2011, Biomaterials.

[33]  D. Barford,et al.  Structural insights into mRNA recognition from a PIWI domain–siRNA guide complex , 2005, Nature.

[34]  G. Di Fabio,et al.  An efficient and versatile solid-phase synthesis of 5'- and 3'-conjugated oligonucleotides. , 2005, Organic letters.

[35]  Hong Zhao,et al.  Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers. , 2008, Bioconjugate chemistry.

[36]  Phillip D Zamore,et al.  Evidence that siRNAs function as guides, not primers, in the Drosophila and human RNAi pathways. , 2002, Molecular cell.

[37]  Keitaro Yoshimoto,et al.  Direct observation of adsorption-induced inactivation of antibody fragments surrounded by mixed-PEG layer on a gold surface. , 2010, Journal of the American Chemical Society.

[38]  D. Filpula,et al.  Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation. , 2003, Protein engineering.

[39]  F. Davis,et al.  Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. , 1977, The Journal of biological chemistry.

[40]  J. Bomalaski,et al.  Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[41]  A. P. Chapman,et al.  PEGylated antibodies and antibody fragments for improved therapy: a review. , 2002, Advanced drug delivery reviews.

[42]  Y. Nagasaki,et al.  Near-infrared (1550 nm) in vivo bioimaging based on rare-earth doped ceramic nanophosphors modified with PEG-b-poly(4-vinylbenzylphosphonate). , 2011, Nanoscale.

[43]  Magdeline Tao Tao Ng,et al.  Dumbbell‐shaped Circular Oligonucleotides as Inhibitors of Human Topoisomerase I , 2007, Bioorganic & medicinal chemistry letters.

[44]  W. Zhang,et al.  Modification of phosphorothioate oligonucleotides yields potent analogs with minimal toxicity for antisense experiments in the CNS. , 1998, Brain research. Molecular brain research.

[45]  K. Toh,et al.  Novel redox nanomedicine improves gene expression of polyion complex vector , 2011, Science and technology of advanced materials.

[46]  V. Erdmann,et al.  Synthesis and properties of oligodeoxyribonucleotide-polyethylene glycol conjugates. , 1994, Nucleic acids research.

[47]  Kazuo Maruyama,et al.  Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes , 1990, FEBS letters.

[48]  Hideyoshi Harashima,et al.  A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma. , 2011, Advanced drug delivery reviews.

[49]  A. B. Benson,et al.  A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma , 2008, Cancer Chemotherapy and Pharmacology.

[50]  Y. Nagasaki,et al.  Stimuli-responsive smart nanogels for cancer diagnostics and therapy. , 2010, Nanomedicine.

[51]  Y. Nagasaki,et al.  Novel protein PEGylation chemistry via glutalaldehyde-functionalized PEG. , 2013, Bioconjugate chemistry.

[52]  A. Seifalian,et al.  Exosomes as nano-theranostic delivery platforms for gene therapy. , 2013, Advanced drug delivery reviews.

[53]  P. Hadwiger,et al.  Defined Folate-PEG-siRNA Conjugates for Receptor-specific Gene Silencing , 2012, Molecular therapy. Nucleic acids.

[54]  Keitaro Yoshimoto,et al.  Creation of a mixed poly(ethylene glycol) tethered-chain surface for preventing the nonspecific adsorption of proteins and peptides , 2007, Biointerphases.

[55]  A. Plückthun,et al.  Protein PEGylation Decreases Observed Target Association Rates via a Dual Blocking Mechanisms⃞ , 2005, Molecular Pharmacology.

[56]  T. Oda,et al.  Preparation of highly dispersible and tumor-accumulative, iron oxide nanoparticles Multi-point anchoring of PEG-b-poly(4-vinylbenzylphosphonate) improves performance significantly. , 2011, Colloids and Surfaces B: Biointerfaces.

[57]  C Simone Fishburn,et al.  The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. , 2008, Journal of pharmaceutical sciences.

[58]  T. Rana,et al.  siRNA function in RNAi: a chemical modification analysis. , 2003, RNA.

[59]  D. Filpula,et al.  Releasable PEGylation of proteins with customized linkers. , 2008, Advanced drug delivery reviews.

[60]  T. Niidome,et al.  Stabilizing of plasmid DNA in vivo by PEG-modified cationic gold nanoparticles and the gene expression assisted with electrical pulses. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[61]  D. Ribatti,et al.  Tumor Regression and Curability of Preclinical Neuroblastoma Models by PEGylated SN38 (EZN-2208), a Novel Topoisomerase I Inhibitor , 2010, Clinical Cancer Research.

[62]  K. Kataoka,et al.  Combination of chondroitin sulfate and polyplex micelles from Poly(ethylene glycol)-poly{N'-[N-(2-aminoethyl)-2-aminoethyl]aspartamide} block copolymer for prolonged in vivo gene transfection with reduced toxicity. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[63]  J. M. Harris,et al.  Attachment of degradable poly(ethylene glycol) to proteins has the potential to increase therapeutic efficacy. , 1998, Journal of pharmaceutical sciences.

[64]  V. Torchilin,et al.  Liposomes for targeted delivery of antithrombotic drugs , 2008, Expert opinion on drug delivery.

[65]  P. Zamore,et al.  ATP Requirements and Small Interfering RNA Structure in the RNA Interference Pathway , 2001, Cell.

[66]  Heinrich Leonhardt,et al.  Synthesis of DNA dumbbell based inhibitors for the human DNA methyltransferase Dnmt1. , 2008, Angewandte Chemie.

[67]  Soo Hyun Lee,et al.  PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[68]  T. Okano,et al.  Toxicity and antitumor activity against solid tumors of micelle-forming polymeric anticancer drug and its extremely long circulation in blood. , 1991, Cancer research.

[69]  K. Kataoka,et al.  Biodegradable polyamino acid-based polycations as safe and effective gene carrier minimizing cumulative toxicity. , 2010, Biomaterials.

[70]  Francesco M Veronese,et al.  State of the art in PEGylation: the great versatility achieved after forty years of research. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[71]  T. Kissel,et al.  Controlled pulmonary drug and gene delivery using polymeric nano-carriers. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[72]  Y. Nagasaki,et al.  Facile solid-phase synthesis of a highly stable poly(ethylene glycol)-oligonucleotide conjugate. , 2013, Journal of materials chemistry. B.

[73]  J. Bomalaski,et al.  Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. , 2002, Cancer research.

[74]  Noritada Kaji,et al.  Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEG-lipid. , 2011, Biomaterials.

[75]  K. Kataoka,et al.  Polymeric micelles from poly(ethylene glycol)–poly(amino acid) block copolymer for drug and gene delivery , 2009, Journal of The Royal Society Interface.

[76]  Xing-jie Liang,et al.  Gene transfection efficacy and biocompatibility of polycation/DNA complexes coated with enzyme degradable PEGylated hyaluronic acid. , 2013, Biomaterials.

[77]  Kazunori Kataoka,et al.  PEGylated Nanoparticles for Biological and Pharmaceutical Applications , 2003 .

[78]  Y. Nagasaki,et al.  Block ionomer complexes of PEG-block-poly(4-vinylbenzylphosphonate) and cationic surfactants as highly stable, pH responsive drug delivery system. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[79]  Gideon Schreiber,et al.  Reversible PEGylation: a novel technology to release native interferon alpha2 over a prolonged time period. , 2004, Journal of medicinal chemistry.

[80]  Leaf Huang,et al.  Immunostimulation of dendritic cells by cationic liposomes , 2006, Molecular membrane biology.

[81]  David R Corey,et al.  RNA interference in mammalian cells by chemically-modified RNA. , 2003, Biochemistry.

[82]  Francesco M Veronese,et al.  PEGylation, successful approach to drug delivery. , 2005, Drug discovery today.

[83]  H. Dai,et al.  PEG branched polymer for functionalization of nanomaterials with ultralong blood circulation. , 2009, Journal of the American Chemical Society.

[84]  V. Torchilin,et al.  Polyethyleneimine-lipid conjugate-based pH-sensitive micellar carrier for gene delivery. , 2012, Biomaterials.

[85]  Yitao Wang,et al.  Polymeric micelles drug delivery system in oncology. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[86]  S. S. Kanwar,et al.  Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia. , 2007, Critical reviews in oncology/hematology.

[87]  K. Kataoka,et al.  Preclinical and clinical studies of anticancer agent‐incorporating polymer micelles , 2009, Cancer science.

[88]  Sheela M. Waugh,et al.  2′-Fluoropyrimidine RNA-based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF165) , 1998, The Journal of Biological Chemistry.

[89]  Y. Nagasaki,et al.  Novel oligonucleotide carrier as scavenger for reactive oxygen species. , 2011, Macromolecular bioscience.

[90]  H. Chung,et al.  Gene silencing efficiency of siRNA-PEG conjugates: effect of PEGylation site and PEG molecular weight. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[91]  H. Harashima,et al.  Advances in non-viral gene delivery: using multifunctional envelope-type nano-device , 2008 .

[92]  M. Tamura,et al.  In vitro and in vivo characteristics of core-shell type nanogel particles: optimization of core cross-linking density and surface poly(ethylene glycol) density in PEGylated nanogels. , 2011, Acta biomaterialia.

[93]  Y. Nagasaki,et al.  Enhanced immunoresponse of antibody/mixed-PEG co-immobilized surface construction of high-performance immunomagnetic ELISA system. , 2007, Journal of colloid and interface science.

[94]  M. Maeda,et al.  Synthesis, structure, and biological activity of dumbbell-shaped nanocircular RNAs for RNA interference. , 2011, Bioconjugate chemistry.

[95]  J. Behr,et al.  Systemic linear polyethylenimine (L‐PEI)‐mediated gene delivery in the mouse , 2000, The journal of gene medicine.

[96]  G. Pasut,et al.  Polymer-drug conjugation, recent achievements and general strategies , 2007 .

[97]  Iseult Lynch,et al.  Designing the nanoparticle-biomolecule interface for "targeting and therapeutic delivery". , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[98]  Y. Anraku,et al.  Smart multilayered assembly for biocompatible siRNA delivery featuring dissolvable silica, endosome-disrupting polycation, and detachable PEG. , 2012, ACS nano.

[99]  A. Deiters,et al.  Stabilization and photochemical regulation of antisense agents through PEGylation. , 2011, Bioconjugate chemistry.

[100]  Lawrence X. Yu,et al.  In vitro and in vivo characterizations of PEGylated liposomal doxorubicin. , 2011, Bioanalysis.

[101]  Pierre Lemieux,et al.  Block copolymeric biotransport carriers as versatile vehicles for drug delivery , 2001, Expert opinion on investigational drugs.